Small Grants Program first deadline is June 15th. Please visit us
online at www.preventpneumo.org
for more information about the program and application procedures.
After May 30, 2004 please visit our website at www.preventpneumo.org
to learn more about our Request for Applications to prepare field
sites for potential large-scale evaluation of pneumococcal conjugate
vaccine impact in Asia.
For ISPPD-4 highlights please see PneumoADIP’s daily special
editions of PneumoFOCUS at www.preventpneumo.org.
|STUDY SHOWS PNEUMOCOCCAL CONJUGATE VACCINES TO BE COST-EFFECTIVE IN WORLD'S POOREST COUNTRIES
May 12 – Dr. Anushua Sinha presented data today at
ISPPD-4 from a recently completed PneumoADIP-sponsored study exploring
the cost-effectiveness of a pneumococcal conjugate vaccine in the
world’s 75 poorest countries. In order to make informed health
policy decisions policy makers need better information on the projected
health benefits and cost-effectiveness of the vaccines. This study
will contribute greatly to this information.
Dr. Tracy Lieu headed this investigation
which was conducted at Harvard Medical School’s Harvard Pilgrim
Health Care. Dr. Lieu’s group constructed a model to compare
three possible situations: (1) no vaccine (2) uptake of the vaccine
without Vaccine Fund (VF) support and (3) vaccine uptake with VF financing.
They found that VF financing would prevent 1.92 million deaths from
2011-2020. The authors also found that at $5/dose for a three-dose
regimen the vaccine would cost $US 99/ DALY, below the World Bank
benchmark for cost-effectiveness of per capita Gross National Income
(country range, $90-$1380). A DALY, or Disability Adjusted Life Year,
is the World Bank and WHO’s unit for measuring the global burden
of disease and the effectiveness of health interventions. As vaccine
cost increased to $10 per dose, the cost of an averted DALY increased
to $US 192. In the worst-case scenario, the cost of an averted DALY
was $902. The authors are now working on WHO region-level analyses
that will be extremely useful to regional policy makers.
|PNEUMOADIP IS FIRST TO SPONSOR ISPPD-5
is proud to be the first sponsor of the 5th International Symposium
on Pneumococci and Pneumococcal Disease, April 30 – May 4, 2006
in Alice Springs, Australia.
The official launch of ISPPD-5 was done during the closing remarks
of the ISPPD-4 meeting in Helsinki, Finland. It was there that the
organizing committee announced PneumoADIP as the first official sponsor
of the upcoming Australian meeting. PneumoADIP has pledged $US 10,000
and promised to match any other early sponsorships with additional
funds up to $US 50,000.
Alice Springs is located in the heart of Australia and is often referred
to as the capital of the outback. It has been chosen as an appropriate
venue because the burden of invasive pneumococcal disease in young
central Aboriginal children is among the highest in the world. “We
are honored to have the opportunity of hosting the meeting in Australia,”
say Professor Allan Cripps and Dr. Amanda Leach.
For more information please visit the ISPPD-5 website at www.isppd5.com.
|RESEARCHERS UNDERSTAND GLOBAL BURDEN OF PNEUMOCOCCAL DISEASE
May 13 – The results of a short, PneumoADIP-conducted
survey of 130 conference participants at the ISPPD-4 meeting here
gave a snapshot of experts’ impressions of pneumococcal disease.
Short interviews with delegates asked attendees for their estimates
of yearly child deaths from pneumococcal disease; which disease out
of malaria, rotavirus and pneumococcal disease kill the most children
in developing countries each year; and whether or not they believed
pneumococcal conjugate vaccines could be made affordable to developing
Participants generally had relatively accurate
understanding of the global burden of pneumococcal disease although
they slightly overestimated in general. 73% of interviewees believed
that 1 million or more children die each year from pneumococcal
disease while the current WHO estimate is 841,000 deaths. About
half of participants accurately supposed that pneumococcal disease
kills the most children in developing countries out of the three
choices given. And finally, participants are optimistic about the
possibility of making the pneumococcal conjugate vaccine affordable
in the developing world – 63% said they believed the vaccines
could be made affordable.